IRulya Therapeutics Appoints Brigette Roberts as Chief Executive Officer
PRIVATEOct 30, 2026
Position
Chief Financial Officer
Company
IRulya Therapeutics
John Militello
BiotechnologyHealth CareTherapeutics
Description
IRulya Therapeutics announced a management transition with Brigette Roberts being appointed as chief executive officer, John Militello as chief financial officer, and Keith Fandrick as chief operating officer. This change follows the company's corporate rebranding from Quince Therapeutics.
Who to call at IRulya Therapeutics, and when
A new leader at IRulya Therapeutics brings new priorities and often new vendors. The first weeks are when they listen.
An alert the day IRulya Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at IRulya Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at IRulya Therapeutics. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
IRulya Therapeutics
About
IRulya Therapeutics, formerly known as Quince Therapeutics, is focused on developing LAM-001, a once-daily dry-powder inhaled formulation of rapamycin. The company targets multiple pulmonary indications and has ongoing studies related to pulmonary hypertension and other conditions. IRulya aims to enhance pulmonary delivery while minimizing systemic exposure.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment IRulya Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
